New drug cocktail shows promise for rare sarcomas

NCT ID NCT04216953

Completed Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured how many had their disease controlled after 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cobimetinib (a MEK inhibitor) and atezolizumab (a PDL1 inhibitor)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced soft tissue sarcoma, potentially slowing tumor growth.
What could go wrong: This is an early-phase trial with a small number of patients, so results may not lead to a standard treatment. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant peripheral nerve sheath tumor rhabdomyosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA,SOFT TISSUE

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59020, France
Hôpital de la Timone

Marseille, 13385, France
Institut Curie

Paris, France
Institut Gustave Roussy

Villejuif, 94800, France
Institut de Cancérologie de l'Ouest

Angers, 49055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.